Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06986382 · ClinicalTrials.gov registry record · Phase 1
Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease
A Phase 1 study, sponsored by Stanford University.
- Not yet
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT06986382: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT06986382 is a Phase 1 study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06986382, a Phase 1 study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This research study is investigating whether alpha beta T-cell depleted hematopoietic stem cell transplant (HSCT) can be an immune system replacement for Crohn disease patients and whether this is safe and effective for patients with early onset, medically refractory Crohn disease.
Interventions
- DRUG Palifermin
- DRUG ATG
- DRUG Clofarabine
- DEVICE CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System
- DRUG Prednisone/Methylprenisolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2025-07 |
| Est. Completion | 2040-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06986382
The ClinicalTrials.gov registry entry for NCT06986382 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Palifermin is the first listed.
NCT06986382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06986382 about?
NCT06986382 is a clinical study titled "Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease". This research study is investigating whether alpha beta T-cell depleted hematopoietic stem cell transplant (HSCT) can be an immune system replacement for Crohn disease patients and whether this is safe and effective for patients with early onset, medically refractory Crohn disease.
What is the current status of trial NCT06986382?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2025-07. Estimated completion is 2040-07.
What interventions are being tested in trial NCT06986382?
The interventions under investigation include: Palifermin (DRUG), ATG (DRUG), Clofarabine (DRUG), CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System (DEVICE), Prednisone/Methylprenisolone (DRUG).
Who is sponsoring clinical trial NCT06986382?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.